Skip to main content

Table 1 Patient details and antibody frequencies

From: In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype

 

n (%)

 

Polymyositis

Dermatomyositis

 

(n = 117)

(n = 108)

Females

81 (69.2)

75 (69.4)

Average age of onseta

50.4 ± 14.5

49.0 ± 14.1

Interstitial lung disease

18 (15.4)

19 (17.6)

Malignancyb

2 (1.7)

14 (13.0)

Antibody status

(n = 105)

(n = 101)

Myositis-specific antibodies

  

   Jo-1

24 (22.9)

22 (21.8)

   PL-7

1 (1.0)

0

   PL-12

0

1 (1.0)

   EJ

0

1 (1.0)

   OJ

1 (1.0)

1 (1.0)

   KS

1 (1.0)

1 (1.0)

   Any of the abovec

27 (25.7)

25 (24.7)

   Mi-2d

1 (1.0)

17 (16.8)

   SRP

5 (4.8)

2 (2.0)

Myositis-associated antibodies

  

   U1-RNP

5 (4.8)

8 (7.9)

   U3-RNP

0

2 (2.0)

   Ku

0

2 (2.0)

   PM-Scl

5 (4.8)

6 (5.9)

None of the above autoantibodies

62 (59.1)

45 (44.5)

  1. aResults expressed as mean ± standard deviation. bDermatomyositis (DM) versus polymyositis (PM), p = 0.001; odds ratio (OR) 8.6, (95% confidence interval (CI) 1.9–78.9). cThe total for DM is 25 despite the presence of 26 anti-tRNA synthetases, due to one patient possessing both anti-Jo-1 and anti-PL-12. dDM versus PM, p = 2.9 × 10-5; OR 21.0 (95% CI 3.1–887.7).